About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels. Main lines of research:
PMID: 34554648 Journal: AMERICAN JOURNAL OF TRANSPLANTATION Year: 2022 Reference: Am J Transplant. 2022 Feb;22(2):673-675. doi: 10.1111/ajt.16855. Epub 2021 Oct 5. Impact factor: 8.086 Publication type: Letter or abstract Authors: Toapanta, Nestor; Esperalba, Juliana; Campos-Varela, Isabel; Pont, Teresa; Len, Oscar; Campins, Magda; Moreso, Francesc; Crespo, Elena; Munoz, Marina; Lopez, Manuel et al. DOI: 10.1111/ajt.16855
PMID: 34961900 Journal: Infectious Diseases and Therapy Year: 2022 Reference: Infect Dis Ther. 2022 Feb;11(1):463-483. doi: 10.1007/s40121-021-00571-y. Epub 2021 Dec 27. Impact factor: 5.322 Publication type: Paper in international publication Authors: Dos Santos, Gael; Wang, Hao; Jindal, Pooja; Rybo, Maria; Roul, Helene; Pallem, Sridevi; Eckermann, Tamara; Godderis, Lode; Martinez Gomez, Xavier; Godard, Eric et al. DOI: 10.1007/s40121-021-00571-y
PMID: 35740839 Journal: Children-Basel Year: 2022 Reference: Children (Basel). 2022 Jun 16;9(6). pii: children9060902. doi: 10.3390/children9060902. Impact factor: 2.863 Publication type: Paper in international publication Authors: Izurieta-Pacheco, Ana Carolina; Fresan-Ruiz, Elena; Girona-Alarcon, Monica; de Carlos-Vicente, Juan Carlos; Belda-Hofheinz, Sylvia; Nieto-Moro, Montserrat; Uriona-Tuma, Sonia Maria; Pinos-Tella, Laia; Morteruel-Arizcuren, Elvira; Schuffelmann, Cristina et al. DOI: 10.3390/children9060902
PMID: 35752569 Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Year: 2022 Reference: Enferm Infecc Microbiol Clin (Engl Ed). 2022 Jun 22. pii: S2529-993X(22)00132-0. doi: 10.1016/j.eimce.2022.06.002. Impact factor: 1.731 Publication type: Paper in international publication Authors: Ruiz-Botia, Irene; Riera-Bosch, M Teresa; Rodriguez-Losada, Olalla; Soler-Palacin, Pere; Melendo, Susana; Moraga-Llop, Fernando; Balcells-Ramirez, Joan; Otero-Romero, Susana; Armadans-Gil, Lluis et al. DOI: 10.1016/j.eimce.2022.06.002
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.
El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.
